A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Daclatasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms COMMIT
- Sponsors Janssen-Cilag
- 04 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Interim results (n=106) presented at The International Liver Congress™ 2016
- 11 Apr 2016 Data will be presented at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL), according to a Medivir AB media release.